The Rickets drugs in development market research report provides comprehensive information on the therapeutics under development for Rickets, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rickets. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rickets and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Rickets by ten companies/universities/institutes. The top development phase for Rickets is preclinical with seven drugs in that stage. The Rickets pipeline has eight drugs in development by companies and two by universities/ institutes. Some of the companies in the Rickets pipeline products market are: Kyowa Kirin, Inozyme Pharma and Aptacure Therapeutics.
The key targets in the Rickets pipeline products market include Fibroblast Growth Factor 23, Fibroblast Growth Factor Receptor, and Growth Hormone Receptor.
The key mechanisms of action in the Rickets pipeline product include Fibroblast Growth Factor 23 Inhibitor with five drugs in Pre-Registration. The Rickets pipeline products include three routes of administration with the top ROA being Subcutaneous and six key molecule types in the Rickets pipeline products market including Monoclonal Antibody, and Fusion Protein.
Rickets overview
Rickets is a childhood disease where the bones are too soft and weak, causing them to warp, bend, and break easily. Widening of the knees, bone pain, pigeon chest, growth delay, and rachitic rosary are the symptoms of rickets. It is caused due to nutritional deficiency (vitamin D, calcium) or genetic condition that affect vitamin D absorption. X-rays, blood and urine tests, bone biopsies and genetic testing are used for diagnosis. High doses of vitamin D in diet or as a supplement, exposure to sunlight, and calcium are the treatment options.
For a complete picture of Rickets’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
